Loading stock…

CareDx, Inc. (CDNA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

CareDx, Inc.

CDNAMarket cap $3.26BPrice $63.0

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

CareDx develops genetic testing that tells doctors whether a transplanted organ is being rejected, using a simple blood draw instead of invasive biopsies. It dominates the transplant surveillance market, monitoring patients who'd otherwise need painful, repeated tissue samples.

In Bastion Portfolios?

52W Return+337%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+6%5

Revenue Forecast

Rev CAGR (1y)+30%9

Rev CAGR (3y)+17%9

Rev CAGR (5y)+16%9

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+7%6

EPS Growth Y+3+43%9

Quality

Margins

EBIT Margin-0%1

Net Income Margin24%8

Free Cash Flow Margin18%8

Debt

Net Debt/EBITDA-17.910

Efficiency

ROE29%9

ROA23%10

Earnings Stability44

GEAR+STRONG68

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)571

P/E Ratio (Forward 3y)331

P/BV7.72

EV Multiples

EV/EBITDA Fwd411

EV/EBIT Fwd282

Yield

Free Cash Flow Yield2.6%4

Dividend Yieldna–

Momentum

Short term

1 month return+25%10

3 month return+129%10

YTD return+235%10

Mid term

Price vs 52wHigh87%7

1 year return+326%10

Long term

3 year return+868%10

5 year return+1%4

Risk Shield

Price Risk

Beta0.94

Volatility69%2

Free Cash Flow

Free Cash Flow Margin18%8

Free Cash Flow Yield2.6%4

Quality

ROCE-0%1

Earnings Stability44

Net Debt/EBITDA-17.910

02Growth

Is it actually growing, and how fast?

CDNACareDx

Revenue FY25$380M

GROWTH RATING↗

STRONG84 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+30%9

Revenue, next 3Y, CAGR+17%9

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+7%6

EPS growth, FY28E+43%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 84% of companies worldwide.

Revenue is set to grow 17%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 6%/yr over the last 3 years and is set to grow 17%/yr from here.

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

WATCH

Earnings are set to grow slower than sales (EPS about 7%/yr vs revenue 17%/yr), so margins are under pressure.

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's speeding up. The one thing to watch: earnings are set to grow slower than sales.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG93 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+25%10

3-month return+129%10

YTD return+235%10

MID & LONG-TERM▾SCORE

% of 52-week high87%7

1-year return+326%10

3-year return+868%10

5-year return+1%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +868% over three years and +0.7% over five, ahead of 60% of the market.

It's up 326% over the past year, but 13% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+25%), over three months (+129%) and so far this year (+235%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on CareDx, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CDNACareDx

Revenue FY25$380M

GROWTH RATING↗

STRONG84 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+30%9

Revenue, next 3Y, CAGR+17%9

Revenue, next 5Y, CAGR+16%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+7%6

EPS growth, FY28E+43%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 84% of companies worldwide.

Revenue is set to grow 17%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 6%/yr over the last 3 years and is set to grow 17%/yr from here.

The runway holds up: revenue is set to grow 16%/yr over five years.9/10

WATCH

Earnings are set to grow slower than sales (EPS about 7%/yr vs revenue 17%/yr), so margins are under pressure.

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's speeding up. The one thing to watch: earnings are set to grow slower than sales.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG93 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+25%10

3-month return+129%10

YTD return+235%10

MID & LONG-TERM▾SCORE

% of 52-week high87%7

1-year return+326%10

3-year return+868%10

5-year return+1%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +868% over three years and +0.7% over five, ahead of 60% of the market.

It's up 326% over the past year, but 13% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+25%), over three months (+129%) and so far this year (+235%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on CareDx, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community